Literature DB >> 23412691

Efficacy of adalimumab therapy for life-threatening pulmonary vasculitis in Behçet's disease.

Suhail Aamar1, Hagit Peleg, David Leibowitz, Tova Chajek-Shaul, Nurith Hiller, Samuel N Heyman.   

Abstract

Inflammatory large-vessel vasculitis in Behçet's disease may cause life-threatening arterial aneurysms that are prone to rupture. We report a patient with Behçet's disease with right ventricular thrombus and large aneurysms of the pulmonary arteries that led to recurrent episodes of hemoptysis. Following relapses and only partial response to repeated courses of cyclophosphamide and steroids, the patient was treated with adalimumab (Humira) and is now in clinical remission for over 30 months, with regression of her pulmonary lesions. Anti-TNFα treatment is a potential therapeutic option in patients with life-threatening complications due to large-vessel vasculitis.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23412691     DOI： 10.1007/s00296-013-2693-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  19 in total

1.  Behçet's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis.

Authors:  Sabine Adler; Iris Baumgartner; Peter M Villiger
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

2.  Switching to adalimumab is effective in a case of neuro-Behcet's disease refractory to infliximab.

Authors:  Pietro Leccese; Salvatore D'Angelo; Padula Angela; Gabriella Coniglio; Ignazio Olivieri
Journal:  Clin Exp Rheumatol       Date:  2010-09-24       Impact factor: 4.473

3.  Successful treatment of leg ulcers in Behçet's disease using adalimumab plus methotrexate after the failure of infliximab.

Authors:  Fabiola Atzeni; Pietro Leccese; Salvatore D'Angelo; Piercarlo Sarzi-Puttini; Ignazio Olivieri
Journal:  Clin Exp Rheumatol       Date:  2010-09-24       Impact factor: 4.473

4.  Echocardiographic manifestations of Adamantiades-Behcet's disease.

Authors:  David Leibowitz; David Planer; Tova Chajek-Shaul
Journal:  Eur J Echocardiogr       Date:  2006-09-28

Review 5.  Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.

Authors:  Piergiorgio Neri; Manuela Zucchi; Pia Allegri; Marta Lettieri; Cesare Mariotti; Alfonso Giovannini
Journal:  Int Ophthalmol       Date:  2011-02-02       Impact factor: 2.031

6.  Efficacy of switching to adalimumab in a patient with refractory uveitis of Behçet's disease to infliximab.

Authors:  Pietro Leccese; Loredana Latanza; Salvatore D'Angelo; Angela Padula; Ignazio Olivieri
Journal:  Clin Exp Rheumatol       Date:  2011-09-27       Impact factor: 4.473

7.  Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.

Authors:  Ignazio Olivieri; Pietro Leccese; Salvatore D'Angelo; Angela Padula; Angelo Nigro; Carlo Palazzi; Gabriella Coniglio; Loredana Latanza
Journal:  Clin Exp Rheumatol       Date:  2011-09-27       Impact factor: 4.473

Review 8.  Behçet's disease: a new target for anti-tumour necrosis factor treatment.

Authors:  P P Sfikakis
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

9.  Cytokine production profile in patients with Behcet's disease treated with infliximab.

Authors:  Midori Misumi; Eri Hagiwara; Mitsuhiro Takeno; Yukiko Takeda; Yuko Inoue; Takashi Tsuji; Atsuhisa Ueda; Satoshi Nakamura; Shigeaki Ohno; Yoshiaki Ishigatsubo
Journal:  Cytokine       Date:  2003-12-07       Impact factor: 3.861

10.  Adalimumab treatment for life threatening pulmonary artery aneurysm in Behçet disease: a case report.

Authors:  Sung-Won Lee; Sang-Yeob Lee; Ki-Nam Kim; Jin-Kyu Jung; Won-Tae Chung
Journal:  Clin Rheumatol       Date:  2009-10-09       Impact factor: 2.980
View more
  4 in total

Review 1.  Treating the Different Phenotypes of Behçet's Syndrome.

Authors:  Alessandra Bettiol; Gulen Hatemi; Lorenzo Vannozzi; Alessandro Barilaro; Domenico Prisco; Giacomo Emmi
Journal:  Front Immunol       Date:  2019-12-06       Impact factor: 7.561

2.  The Clinical Features, Risk Factors, and Outcome of Aneurysmal Lesions in Behcet's Disease.

Authors:  Jiaxin Zhou; Jing Shi; Jinjing Liu; Luxi Sun; Lu Li; Chaoran Li; Xiuhua Wu; Yining Wang; Xinping Tian; Xiaofeng Zeng; Yi Liu; Wenjie Zheng; Yan Zhao
Journal:  J Immunol Res       Date:  2019-12-20       Impact factor: 4.818

3.  Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.

Authors:  Antonio Vitale; Giacomo Emmi; Giuseppe Lopalco; Stefano Gentileschi; Elena Silvestri; Claudia Fabiani; Maria Letizia Urban; Bruno Frediani; Mauro Galeazzi; Florenzo Iannone; Donato Rigante; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2016-09-27       Impact factor: 3.650

Review 4.  Spontaneous Intra-Abdominal Hemorrhage Due to Rupture of Jejunal Artery Aneurysm in Behcet Disease: Case Report and Literature Review.

Authors:  Xiao-Yan Wu; Jiang-Peng Wei; Xiu-Yuan Zhao; Yue Wang; Huan-Huan Wu; Tao Shi; Tong Liu; Gang Liu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.